Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Enterprise Value (2016 - 2026)

China Pharma Holdings filings provide 16 years of Enterprise Value readings, the most recent being -$345112.0 for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 44.95% to -$345112.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$345112.0, a 44.95% increase, with the full-year FY2025 number at -$345112.0, up 44.95% from a year prior.
  • Enterprise Value hit -$345112.0 in Q4 2025 for China Pharma Holdings, down from -$300000.0 in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$300000.0 in Q3 2025 to a low of -$4.9 million in Q4 2021.
  • Median Enterprise Value over the past 5 years was -$870395.5 (2023), compared with a mean of -$1.4 million.
  • Biggest five-year swings in Enterprise Value: tumbled 642.96% in 2022 and later skyrocketed 68.59% in 2023.
  • China Pharma Holdings' Enterprise Value stood at -$4.9 million in 2021, then surged by 58.22% to -$2.0 million in 2022, then grew by 29.86% to -$1.4 million in 2023, then surged by 55.97% to -$626879.0 in 2024, then skyrocketed by 44.95% to -$345112.0 in 2025.
  • The last three reported values for Enterprise Value were -$345112.0 (Q4 2025), -$300000.0 (Q3 2025), and -$625032.0 (Q2 2025) per Business Quant data.